NEW YORK – GenomOncology and Precipio announced Wednesday that they have partnered to integrate GenomOncology's clinical genomic reporting software with Precipio's test for myeloid neoplasms.

纽约——GenomOncology和Precipio周三宣布，他们已合作将GenomOncology的临床基因组报告软件与Precipio的髓样肿瘤检测相结合。

Under the partnership, GenomOncology's Pathology Workbench will be used as the tertiary analysis and clinical genomic reporting platform for Precipio's next-generation sequencing-based test for myeloid neoplasms. GenomOncology's software will provide support for variant filtering and interpretation, case review, customizable reporting, and matching appropriate therapy and clinical trial options to each patient, the companies said in a statement..

在该合作伙伴关系下，GenomOncology的病理学工作台将被用作Precipio下一代基于测序的骨髓肿瘤检测的三级分析和临床基因组报告平台。GenomOncology公司在一份声明中表示，该软件将为变异过滤和解释、病例审查、可定制报告以及为每位患者匹配适当的治疗和临床试验选项提供支持。。

'The robust knowledgebase embedded in the GenomOncology Pathology Workbench will empower Precipio to advance variant interpretation for their NGS testing,' GenomOncology Chief Commercial Officer Garreth Hippe said in a statement. 'The solution will accelerate the entire process, from sample to the clinical genomic report, giving healthcare providers faster insights into recommended treatment options.' .

GenomOncology首席商务官加雷思·希佩（GarrethHippe）在一份声明中说：“基因组学病理学工作台中嵌入的强大知识库将使Precipio能够为其NGS测试推进变体解释。”该解决方案将加速从样本到临床基因组报告的整个过程，使医疗保健提供者更快地了解推荐的治疗方案。”。

The software's knowledgebase includes annotations, evidence, clinical trial data, and therapy approvals and guidelines for automated interpretation, the companies noted. It can also be used with additional testing modalities like immunohistochemistry, karyotype, or fluorescence in situ hybridization..

这些公司指出，该软件的知识库包括注释、证据、临床试验数据、治疗批准和自动解释指南。它还可以与其他测试方式一起使用，例如免疫组织化学，核型或荧光原位杂交。。

Financial and other terms of the deal were not disclosed.

交易的财务和其他条款未披露。